"In House" assays for the quantification of Annexin V and its autoantibodies in patients with recurrent pregnancy loss and in vitro fertilisation failures.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
received:
03
04
2023
accepted:
12
12
2023
medline:
16
12
2023
pubmed:
16
12
2023
entrez:
15
12
2023
Statut:
epublish
Résumé
Several studies have been shown that Annexin V (ANXV) autoantibodies concentrations are associated with both early recurrent pregnancy losses (RPLs) or in vitro fertilization failure (IVFf). We investigated the association between ANXV autoantibodies and ANVX levels in RPL, IVFf and normal group women. The study was conducted on 22 female patients with RPLs, 66 patients with IVFf, and 16 normal samples from women who had given birth. ANXV autoantibodies were measured using an ELISA test developed by fixing a homemade recombinant ANXV protein and examined with labeled human antibodies, while ANXV concentrations were measured by a competitive ELISA using a homemade anti ANXV polyclonal antibody. The results showed a clear relationship between the high levels of ANXV autoantibodies and the recurrent abortion. On the other hand, ANXV measurement in those patients showed decreased concentrations compared to normal samples. Negative correlation between ANXV and its autoantibodies levels was reported in almost all patients' samples. Our data supports the possibility that ANXV autoantibodies are a risk factor for reproductive failures associated with both RPLs and/or IVFf and the significant role for ANXV in the maintenance of pregnancy.
Identifiants
pubmed: 38102468
doi: 10.1038/s41598-023-49768-w
pii: 10.1038/s41598-023-49768-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22322Informations de copyright
© 2023. The Author(s).
Références
Rai, R. & Regan, L. Recurrent miscarriage. Lancet 368, 601–611 (2006).
pubmed: 16905025
doi: 10.1016/S0140-6736(06)69204-0
El Hachem, H. et al. Recurrent pregnancy loss: Current perspectives. Int. J. Womens Health 9, 331–345 (2017).
pubmed: 28553146
pmcid: 5440030
doi: 10.2147/IJWH.S100817
Vomstein, K. et al. Immunological risk factors in recurrent pregnancy loss: Guidelines versus current state of the art. J. Clin. Med. 10, 869 (2021).
pubmed: 33672505
pmcid: 7923780
doi: 10.3390/jcm10040869
Barbhaiya, M. et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 75, 1687–1702 (2023).
pubmed: 37635643
doi: 10.1002/art.42624
Zuo, Y., Shi, H., Li, C. & Knight, J. S. Antiphospholipid syndrome: A clinical perspective. Chin. Med. J. 133, 929–940 (2020).
pubmed: 32265421
pmcid: 7176446
doi: 10.1097/CM9.0000000000000705
Truglia, S. et al. “Non-criteria antiphospholipid antibodies”: Bridging the gap between seropositive and seronegative antiphospholipid syndrome. Rheumatology 61, 826–833 (2022).
pubmed: 33970223
doi: 10.1093/rheumatology/keab414
Matsubayashi, H. et al. Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil. Steril. 76, 694–699 (2001).
pubmed: 11591400
doi: 10.1016/S0015-0282(01)02009-X
Zammiti, W. et al. Antibodies to beta2-glycoprotein I and annexin V in women with early and late idiopathic recurrent spontaneous abortions. Arch. Gynecol. Obstet. 274, 261–265 (2006).
pubmed: 16826414
doi: 10.1007/s00404-006-0158-7
Funakoshi, T., Hendrickson, L. E., McMullen, B. A. & Fujikawa, K. Primary structure of human placental anticoagulant protein. Biochemistry 26, 8087–8092 (1987).
pubmed: 2964863
doi: 10.1021/bi00399a011
Tait, J. F., Gibson, D. & Fujikawa, K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J. Biol. Chem. 264, 7944–7949 (1989).
pubmed: 2524476
doi: 10.1016/S0021-9258(18)83133-7
Reutelingsperger, C. P., Hornstra, G. & Hemker, H. C. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur. J. Biochem. 151, 625–629 (1985).
pubmed: 3896792
doi: 10.1111/j.1432-1033.1985.tb09150.x
Funakoshi, T., Heimark, R. L., Hendrickson, L. E., McMullen, B. A. & Fujikawa, K. Human placental anticoagulant protein: Isolation and characterization. Biochemistry 26, 5572–5578 (1987).
pubmed: 2960376
doi: 10.1021/bi00391a053
Bakar, F., Unlütürk, U., Başkal, N. & Nebioğlu, S. Annexin V expression and anti-annexin V antibodies in type 1 diabetes. J. Clin. Endocrinol. Metab. 99, 932–937 (2014).
pubmed: 24423325
doi: 10.1210/jc.2013-2592
Lizarbe, M. A., Barrasa, J. I., Olmo, N., Gavilanes, F. & Turnay, J. Annexin-phospholipid interactions. Functional implications. Int. J. Mol. Sci. 14, 2652–2683 (2013).
pubmed: 23358253
pmcid: 3588008
doi: 10.3390/ijms14022652
Iaccarino, L. et al. Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseases. Autoimmun. Rev. 10, 553–558 (2011).
pubmed: 21527362
doi: 10.1016/j.autrev.2011.04.007
Satoh, A. et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheumatol. 26, 1715–1720 (1999).
pubmed: 10451067
Esposito, G. et al. Anti-annexin V antibodies: Are they prothrombotic?. Autoimmun. Rev. 4, 55–60 (2005).
pubmed: 15652780
doi: 10.1016/j.autrev.2004.07.006
Rand, J. H. et al. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am. J. Obstet. Gynecol. 177, 918–923 (1997).
pubmed: 9369845
doi: 10.1016/S0002-9378(97)70294-1
Bizzaro, N. et al. A prospective study of 1038 pregnancies on the predictive value of anti-annexin V antibodies for fetal loss. Ann. N. Y. Acad. Sci. 1050, 348–356 (2005).
pubmed: 16014551
doi: 10.1196/annals.1313.037
Sater, M. S., Finan, R. R., Mustafa, F. E., Al-Khateeb, G. M. & Almawi, W. Y. Anti-annexin V IgM and IgG autoantibodies and the risk of idiopathic recurrent spontaneous miscarriage. J. Reprod. Immunol. 89, 78–83 (2011).
pubmed: 21466898
doi: 10.1016/j.jri.2010.12.009
Abbady, A. Q., Twair, A., Ali, B. & Murad, H. Characterization of annexin V fusion with the superfolder GFP in liposomes binding and apoptosis detection. Front. Physiol. 8, 317 (2017).
pubmed: 28579961
pmcid: 5437369
doi: 10.3389/fphys.2017.00317
Nojima, J. et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin. Chem. 47, 1008–1015 (2001).
pubmed: 11375285
doi: 10.1093/clinchem/47.6.1008
Matsuda, J. et al. Anti-annexin antibody in the sera of patients with habitual fetal loss or preeclampsia. Thromb. Res. 75, 105–106 (1994).
pubmed: 8073405
doi: 10.1016/0049-3848(94)90145-7
Mtiraoui, N. et al. Lupus anticoagulant and antibodies to beta 2-glycoprotein I, annexin V, and cardiolipin as a cause of recurrent spontaneous abortion. Fertil. Steril. 88, 1458–1461 (2007).
pubmed: 17548069
doi: 10.1016/j.fertnstert.2007.01.026
Flaherty, M. J., West, S., Heimark, R. L., Fujikawa, K. & Tait, J. F. Placental anticoagulant protein-I: Measurement in extracellular fluids and cells of the hemostatic system. J. Lab. Clin. Med. 115, 174–181 (1990).
pubmed: 2137157
Römisch, J. & Heimburger, N. Purification and characterization of six annexins from human placenta. Biol. Chem. Hoppe Seyler 371, 383–388 (1990).
pubmed: 2143074
doi: 10.1515/bchm3.1990.371.1.383
van Heerde, W. L., de Groot, P. G. & Reutelingsperger, C. P. The complexity of the phospholipid binding protein Annexin V. Thromb. Haemost. 73, 172–179 (1995).
pubmed: 7792726
doi: 10.1055/s-0038-1653747
Rand, J. H. et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am. J. Obstet. Gynecol. 194, 182–188 (2006).
pubmed: 16389029
doi: 10.1016/j.ajog.2005.05.034
Wu, X.-X. et al. Analysis of circulating annexin A5 parameters during pregnancy: Absence of differences between women with recurrent spontaneous pregnancy losses and controls. Am. J. Obstet. Gynecol. 195, 971–978 (2006).
pubmed: 16681990
doi: 10.1016/j.ajog.2006.02.034
Kaneko, N., Matsuda, R., Hosoda, S., Kajita, T. & Ohta, Y. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin. Chim. Acta 251, 65–80 (1996).
pubmed: 8814351
doi: 10.1016/0009-8981(96)06294-8
Matsuda, R. et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation 57, 171–177 (2003).
pubmed: 12745185
doi: 10.1016/S0300-9572(03)00034-0
Van Heerde, W. L. et al. The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma. J. Thromb. Haemost. 1, 532–536 (2003).
pubmed: 12871462
doi: 10.1046/j.1538-7836.2003.00106.x
Peetz, D. et al. Annexin V does not represent a diagnostic alternative to myoglobin for early detection of myocardial infarction. Clin. Lab. 48, 517–523 (2002).
pubmed: 12389712
Römisch, J., Seiffge, D., Reiner, G., Pâques, E. P. & Heimburger, N. In-vivo antithrombotic potency of placenta protein 4 (annexin V). Thromb. Res. 61, 93–104 (1991).
pubmed: 1826976
doi: 10.1016/0049-3848(91)90236-P
Rand, J. H. et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A “lupus procoagulant” phenomenon. Blood 92, 1652–1660 (1998).
pubmed: 9716593
doi: 10.1182/blood.V92.5.1652
Rand, J. H. et al. Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. N. Engl. J. Med. 337, 154–160 (1997).
pubmed: 9219701
doi: 10.1056/NEJM199707173370303
Obringer, A. R., Dean, K. W., Channel, S. R. & Rote, N. S. Aminophospholipid translocase activity in JEG-3; a choriocarcinoma model of cytotrophoblast differentiation. Placenta 18, 421–426 (1997).
pubmed: 9250704
doi: 10.1016/S0143-4004(97)80042-2
Zwaal, R. F. & Schroit, A. J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89, 1121–1132 (1997).
pubmed: 9028933
doi: 10.1182/blood.V89.4.1121
Bozic, B., Irman, S., Gaspersic, N., Kveder, T. & Rozman, B. Antibodies against annexin A5: Detection pitfalls and clinical associations. Autoimmunity 38, 425–430 (2005).
pubmed: 16278147
doi: 10.1080/08916930500288356
Wang, X., Campos, B., Kaetzel, M. A. & Dedman, J. R. Annexin V is critical in the maintenance of murine placental integrity. Am. J. Obstet. Gynecol. 180, 1008–1016 (1999).
pubmed: 10203671
doi: 10.1016/S0002-9378(99)70674-5
Gris, J. C. et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study–NOHA. Thromb. Haemost. 84, 228–236 (2000).
pubmed: 10959694
doi: 10.1055/s-0037-1614001
Gerke, V. & Moss, S. E. Annexins: From structure to function. Physiol. Rev. 82, 331–371 (2002).
pubmed: 11917092
doi: 10.1152/physrev.00030.2001
Haut Donahue, T. L., Genetos, D. C., Jacobs, C. R., Donahue, H. J. & Yellowley, C. E. Annexin V disruption impairs mechanically induced calcium signaling in osteoblastic cells. Bone 35, 656–663 (2004).
pubmed: 15336601
doi: 10.1016/j.bone.2004.04.025
Khalaf, H.-E., Al-Bouqaee, H., Hwijeh, M. & Abbady, A. Q. Characterization of rabbit polyclonal antibody against camel recombinant nanobodies. Open Life Sci. 17, 659–675 (2022).
pubmed: 35800073
pmcid: 9202535
doi: 10.1515/biol-2022-0065
Al-Homsi, L., Al-Okla, S. & Abbady, A. Q. Preparation of specific polyclonal antibody against the recombinant mutacin produced by sfGFP fusion protein technology. Open Microbiol. J. 9, 70–80 (2015).
pubmed: 26668664
pmcid: 4676047
doi: 10.2174/1874285801509010070
Twair, A., Al-Okla, S., Kawas, H. & Abbady, A. Q. Production of polyclonal antibody against M13 phage for application in nanobody technology. Adv. Environ. Biol. 7, 3216–3223 (2013).